Xencor Inc (XNCR) Stock Price, Quote & News

Company Profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to trea...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 305 5900

Website: www.xencor.com

Address:

465 North Halstead Street, Suite 200, Pasadena, United States

Alphatrades09 Jul. 30 at 7:44 PM

$XNCR 17.5C 8/21 — 0.00 → 4.80 (+270%)

0 · Reply

Alphatrades09 Jul. 30 at 4:26 PM

$XNCR 17.5C 8/21 — 0.00 → 4.00 (+207%)

0 · Reply

JFais Jul. 30 at 3:52 PM

$XNCR (L @ 8.5% PW, +70% gain) Really like this price action, new 52-week highs two months ahead of ESMO presentation (ENPP3 in RCC)

0 · Reply

Laynester Jul. 30 at 3:34 PM

$XNCR What this settled suit good news...look at the volume and upward price movement. "Xencor settles Ultomiris royalty dispute with Alexion, to receive $105M and extends cash runway guidance through 2028" Onward! Set a stop. Good to all investors.

0 · Reply

Ravion_News_Filter Jul. 29 at 8:07 PM

$XNCR 🤝 Xencor entered into a settlement agreement with Alexion to receive $105 million in two payments to resolve a commercial dispute over Ultomiris royalties. Timely market event

0 · Reply

HarperLucky Jul. 21 at 11:44 PM

$XNCR Is developing programs targeting autoimmune diseases, including TL1A-related therapies for inflammatory bowel disease (IBD). XmAb942 and XmAb412 are aimed at the large IBD market where better treatments are still needed.

0 · Reply

katorvix Jul. 21 at 11:24 PM

$XNCR is experiencing strong momentum driven by positive clinical trial developments, particularly for XmAb819 in renal cell carcinoma. The stock has broken through multiple resistance levels and achieved pattern targets.

0 · Reply

SmartMoneyTradez Jul. 21 at 8:29 PM

$XNCR multi day

0 · Reply

Laynester Jul. 21 at 7:34 PM

$AGEN $PGEN $XNCR $NAKA $URGN [ZBIO] [CLSK] [XMTR] [VSTM] What is rockin in the portfolio today? HEALTCARE. And MATERIALS making a bottom rebound. Set a stop. Good skills to all peaceful protesters around the world.

1 · Reply

Laynester Jul. 21 at 4:44 PM

$XNCR $DRH $URGN $ESTA $PARR Made some awesome strong buys today. See if you agree. Set a stop. Good skill to all peaceful protesters around the world.

0 · Reply

Xencor participates in a conference call with Cantor

2026-07-29T20:22:00.000Z - 5 days ago

Xencor to receive $105M from Alexion to resolve Ultomiris royalty matter

Jul 29, 2026, 4:01 PM EDT - 5 days ago

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

Jul 17, 2026, 9:11 AM EDT - 18 days ago

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

2026-07-07T13:15:14.000Z - 4 weeks ago

Xencor price target lowered to $27 from $29 at Truist

May 12, 2026, 6:00 PM EDT - 2 months ago

Xencor Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Xencor Slides: Corporate presentation

2026-05-11T13:37:47.000Z - 3 months ago

Xencor price target raised to $14 from $13 at JPMorgan

2026-05-07T01:55:19.000Z - 3 months ago

Xencor reports Q1 EPS ($1.71), consensus (75c)

May 6, 2026, 4:01 PM EDT - 3 months ago

Xencor Reports First Quarter 2026 Financial Results

May 6, 2026, 4:00 PM EDT - 3 months ago

Xencor Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Xencor Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Xencor Transcript: Digestive Disease Week Conference

May 5, 2026, 8:00 AM EDT - 3 months ago

Xencor Slides: Digestive Disease Week Conference

2026-05-04T13:15:10.000Z - 3 months ago

Xencor to host webcast to discuss XmAb942, XmAb412 data presentations

May 4, 2026, 8:01 AM EDT - 3 months ago

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Xencor Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Xencor Proxy statement: Proxy filing

2026-03-24T10:20:13.000Z - 4 months ago

JPMorgan downgrades Xencor on lack of ‘needle-moving’ catalysts

2026-03-24T09:25:28.000Z - 4 months ago

Xencor downgraded to Neutral from Overweight at JPMorgan

Mar 11, 2026, 11:30 AM EDT - 5 months ago

Xencor Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 10:00 AM EDT - 5 months ago

Xencor Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T20:13:44.000Z - 5 months ago

Xencor reports receipt of notice of termination of license agreement from Roche

2026-03-04T21:05:32.000Z - 5 months ago

Xencor expects cash to fund operations into mid-2028

Mar 4, 2026, 4:01 PM EST - 5 months ago

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Mar 2, 2026, 3:50 PM EST - 5 months ago

Xencor Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:01 PM EST - 5 months ago

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 7:00 AM EST - 5 months ago

Xencor Earnings release: Q4 2025

Feb 25, 2026, 7:00 AM EST - 5 months ago

Xencor Annual report: Q4 2025

Feb 23, 2026, 4:01 PM EST - 5 months ago

Xencor to Participate at Upcoming Investor Conferences

Jan 8, 2026, 8:01 AM EST - 7 months ago

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Dec 9, 2025, 7:00 AM EST - 8 months ago

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

Dec 2, 2025, 2:00 PM EST - 8 months ago

Xencor Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 3:00 PM EST - 9 months ago

Xencor Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 6:00 PM EST - 9 months ago

Xencor Slides: Corporate Presentation

Nov 5, 2025, 4:01 PM EST - 9 months ago

Xencor Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 9 months ago

Xencor Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 9 months ago

Xencor Quarterly report: Q3 2025

Oct 24, 2025, 1:30 PM EDT - 10 months ago

Xencor Transcript: Study Result

Oct 24, 2025, 1:30 PM EDT - 10 months ago

Xencor Press release: Study Result

Oct 24, 2025, 1:30 PM EDT - 10 months ago

Xencor Slides: Study Result

Oct 24, 2025, 12:30 PM EDT - 10 months ago

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Oct 21, 2025, 8:01 AM EDT - 10 months ago

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Oct 14, 2025, 12:45 PM EDT - 10 months ago

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Xencor Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:00 PM EDT - 11 months ago

Xencor Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 6, 2025, 4:01 PM EDT - 1 year ago

Xencor Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Xencor Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Xencor Quarterly report: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Xencor Slides: Corporate Presentation

Jul 31, 2025, 4:01 PM EDT - 1 year ago

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

May 7, 2025, 4:01 PM EDT - 1 year ago

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025, 4:00 PM EDT - 1 year ago

Xencor Earnings release: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Xencor Quarterly report: Q1 2025

Apr 29, 2025, 5:00 PM EDT - 1 year ago

Xencor Transcript: Investor Update

Apr 29, 2025, 5:00 PM EDT - 1 year ago

Xencor Press release: Investor Update

Apr 29, 2025, 5:00 PM EDT - 1 year ago

Xencor Slides: Investor Update

Apr 29, 2025, 4:01 PM EDT - 1 year ago

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Xencor Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Xencor Proxy statement: Proxy Filing

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Xencor Appoints Todd Simpson to Board of Directors

Feb 27, 2025, 8:01 AM EST - 1 year ago

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:00 AM EST - 1 year ago

Xencor Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Xencor Earnings release: Q4 2024

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Dec 4, 2024, 3:50 PM EST - 1 year ago

Xencor Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 2:00 PM EST - 1 year ago

Xencor Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Xencor Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 6:00 PM EST - 1 year ago

Xencor Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Xencor Earnings release: Q3 2024

Nov 4, 2024, 7:00 AM EST - 1 year ago

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Oct 10, 2024, 8:09 AM EDT - 1 year ago

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Oct 4, 2024, 8:01 AM EDT - 1 year ago

Xencor Announces Upcoming Change to Board of Directors

Sep 12, 2024, 4:01 PM EDT - 2 years ago

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 11, 2024, 6:31 AM EDT - 2 years ago

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Sep 10, 2024, 4:01 PM EDT - 2 years ago

Xencor Announces Proposed Public Offering of Common Stock

Sep 9, 2024, 7:31 AM EDT - 2 years ago

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Sep 6, 2024, 8:01 AM EDT - 2 years ago

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Aug 5, 2024, 4:01 PM EDT - 2 years ago

Xencor Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:00 PM EDT - 2 years ago

Xencor Quarterly report: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

Xencor Earnings release: Q2 2024

Jun 13, 2024, 8:01 AM EDT - 2 years ago

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

May 15, 2024, 4:40 PM EDT - 2 years ago

Xencor Transcript: Bank of America Health Care Conference 2024

May 14, 2024, 2:05 PM EDT - 2 years ago

Xencor Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 4:09 PM EDT - 2 years ago

Xencor Reports First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 2 years ago

Xencor Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Xencor Earnings release: Q1 2024

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Xencor Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Xencor Proxy statement: Proxy Filing

Apr 9, 2024, 8:01 AM EDT - 2 years ago

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Mar 14, 2024, 11:15 AM EDT - 2 years ago

Xencor Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 13, 2024, 9:20 AM EDT - 2 years ago

Xencor Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 12:50 PM EST - 2 years ago

Xencor Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xencor to Present at Upcoming Investor Conferences

Feb 27, 2024, 4:30 PM EST - 2 years ago

Xencor Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Xencor Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Xencor Earnings release: Q4 2023

Feb 27, 2024, 4:01 PM EST - 2 years ago

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 4:31 PM EST - 2 years ago

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Jan 10, 2024, 6:45 PM EST - 2 years ago

Xencor Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 3, 2024, 4:01 PM EST - 2 years ago

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:01 AM EST - 2 years ago

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

Dec 26, 2023, 12:18 PM EST - 2 years ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Dec 7, 2023, 4:00 PM EST - 2 years ago

Xencor Slides: Corporate Presentation

Nov 28, 2023, 8:00 AM EST - 2 years ago

Xencor Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 4:01 PM EST - 2 years ago

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 4:30 PM EST - 2 years ago

Xencor Earnings Call Transcript: Q3 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Xencor Quarterly report: Q3 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Xencor Earnings release: Q3 2023

Nov 7, 2023, 4:01 PM EST - 2 years ago

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Nov 7, 2023, 4:01 PM EST - 2 years ago

Xencor Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 7:00 AM EST - 2 years ago

Xencor Slides: Corporate Presentation

Nov 3, 2023, 12:01 PM EDT - 2 years ago

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Oct 31, 2023, 4:01 PM EDT - 2 years ago

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Oct 26, 2023, 8:01 AM EDT - 3 years ago

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Sep 27, 2023, 9:01 AM EDT - 3 years ago

Xencor to Present Multiple Posters at the SITC Annual Meeting

Sep 19, 2023, 4:01 PM EDT - 3 years ago

Xencor Appoints Barbara J. Klencke, M.D.

Aug 3, 2023, 4:30 PM EDT - 3 years ago

Xencor Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

Xencor Quarterly report: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

Xencor Earnings release: Q2 2023

Aug 3, 2023, 4:01 PM EDT - 3 years ago

Xencor Reports Second Quarter 2023 Financial Results

Jul 27, 2023, 8:01 AM EDT - 3 years ago

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

May 30, 2023, 6:01 PM EDT - 3 years ago

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Alphatrades09 Jul. 30 at 7:44 PM

$XNCR 17.5C 8/21 — 0.00 → 4.80 (+270%)

0 · Reply

Alphatrades09 Jul. 30 at 4:26 PM

$XNCR 17.5C 8/21 — 0.00 → 4.00 (+207%)

0 · Reply

JFais Jul. 30 at 3:52 PM

$XNCR (L @ 8.5% PW, +70% gain) Really like this price action, new 52-week highs two months ahead of ESMO presentation (ENPP3 in RCC)

0 · Reply

Laynester Jul. 30 at 3:34 PM

0 · Reply

Ravion_News_Filter Jul. 29 at 8:07 PM

$XNCR 🤝 Xencor entered into a settlement agreement with Alexion to receive $105 million in two payments to resolve a commercial dispute over Ultomiris royalties. Timely market event

0 · Reply

HarperLucky Jul. 21 at 11:44 PM

0 · Reply

katorvix Jul. 21 at 11:24 PM

0 · Reply

SmartMoneyTradez Jul. 21 at 8:29 PM

$XNCR multi day

0 · Reply

Laynester Jul. 21 at 7:34 PM

1 · Reply

Laynester Jul. 21 at 4:44 PM

$XNCR $DRH $URGN $ESTA $PARR Made some awesome strong buys today. See if you agree. Set a stop. Good skill to all peaceful protesters around the world.

0 · Reply

JFais Jul. 21 at 3:02 PM

$XNCR (L) New 52s, fun part is this move driven by the asset that provided the most derisking & downside cushion (ENPP3 in RCC) I&I efforts led by TL1A give us greater optionality if you look at deal comps (higher exposure, better immunogenicity + every 12-week dosing vs Gen1)

0 · Reply

Greeek Jul. 21 at 2:56 PM

$4.00 on $XNCR here. 🔥 207% GAIN.

0 · Reply

Alphatrades09 Jul. 21 at 2:41 PM

$XNCR 200%+

0 · Reply

Alphatrades09 Jul. 21 at 2:41 PM

$XNCR 17.5C 8/21 — 0.00 → 4.00 (+207%)

0 · Reply

Marketman707 Jul. 21 at 11:35 AM

$XNCR back to 6 we go!

0 · Reply

StockScanners Jul. 21 at 3:23 AM

$XNCR reached 20.26

0 · Reply

jwordlek Jul. 21 at 12:14 AM

$XNCR I put a stop order at 18.88 when it was trading at 19.12 and it got filed at 18.8 before I tried to change it to the ATR. Bought back again at 18.88 despite that it would be a wash sale.

0 · Reply

Spicy_Trade Jul. 20 at 11:53 PM

Xencor, Inc. ( $XNCR ) SpicyTrade - Daily Stock Analysis https://youtu.be/qmbpzNnIUK4?si=4zjymsd8oSGrHemU

0 · Reply

Greeek Jul. 20 at 3:00 PM

$3.00 on $XNCR here. 🔥 130% GAIN.

0 · Reply

SmartMoneyTradez Jul. 20 at 2:21 PM

$XNCR on watch $SPCQ On scanner daily since 7/13 (Multi day runner). 2X leveraged shorting SpaceX. Once it stops showing up, I'll consider buying $SPCX

0 · Reply

JFais Jul. 20 at 2:01 PM

$XNCR - nice continuation move today Good reminder that holding high conviction names can be like watching paint dry at times, but gets fun when news flow confirms thesis 👍

0 · Reply

Estimize Jul. 20 at 11:01 AM

Wall St is expecting -0.81 EPS for $XNCR Q2 [Reporting 08/05 AMC] http://www.estimize.com/intro/xncr?chart=historical&metric_name=eps&utm_c

0 · Reply

Market Cap	1.50B
Revenue (ttm)	125.58M
Net Income (ttm)	-91.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-73.20%
Debt to Equity Ratio	0.00

Volume	406,558
Avg Vol	950,134
Day's Range	N/A - N/A
Shares Out	74.14M
Stochastic %K	20%
Beta	0.86
Analysts	Strong Sell
Price Target	$28.33